Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced its financial results for 2023, reporting a substantial year-on-year (YOY) increase of 384.2%, with revenues reaching RMB 104.6 million (USD 14.43 million). The significant growth is attributed to the sales of its core products: the Toumai endoscopic surgery robot, SkyWalker hip and knee joint replacement surgery robot, and Dragonfly Eye 3D electronic intraperitoneal endoscopy.
The company’s sales and marketing expenses rose by 29.6% YOY to RMB 238.4 million, driven by increased labor costs from the completion of its commercial promotion and marketing teams by the end of 2022, as well as increased investment in the launch and promotion of its core and flagship products. On the R&D front, costs decreased by 24.7% YOY to RMB 569.2 million, primarily due to the company’s focus on late-stage product pipeline development and enhancements in R&D efficiency.
The Toumai endoscopic surgery robot, a first for domestic peers, received its initial overseas order at the end of last year and has since accumulated 15 overseas sales orders. The product has successfully facilitated over 100 robot-assisted surgeries and achieved multiple consecutive successful operations.- Flcube.com
